ATRA — Atara Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $61.78m
- $89.71m
- $128.94m
- 12
- 72
- 58
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 541.71% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.65% | ||
| Return on Equity | n/a | ||
| Operating Margin | -6.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 20.34 | 63.57 | 8.57 | 128.94 | 67.05 | 31.67 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Directors
- Ronald Renaud CHM (52)
- Pascal Touchon PRE (58)
- Utpal Koppikar CFO (50)
- Joseph Newell COO (51)
- Jakob Dupont EVP (56)
- K. Amar Murugan SVP (46)
- Kristin Yarema SVP (50)
- Carol Gallagher LED (56)
- Ameet Mallik DRC (49)
- Maria Roncarolo DRC (66)
- Roy Baynes IND (66)
- Eric Dobmeier IND (52)
- Matthew Fust IND (56)
- William Heiden IND (61)
- Beth Seidenberg IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 22nd, 2012
- Public Since
- October 16th, 2014
- No. of Shareholders
- 5
- No. of Employees
- 89
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 6,693,146
- Address
- 1280 Rancho Conejo Blvd, THOUSAND OAKS, 91320
- Web
- https://www.atarabio.com/
- Phone
- +1 8056234211
- Contact
- Amber Daugherty
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ATRA
Q3 2025 Atara Biotherapeutics Inc Earnings Release
Similar to ATRA
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Atara Biotherapeutics share price?
As of Today at 19:25 UTC, shares in Atara Biotherapeutics are trading at $9.23. This share price information is delayed by 15 minutes.
How has the Atara Biotherapeutics share price performed this year?
Shares in Atara Biotherapeutics last closed at $9.23 and the price had moved by -9.06% over the past 365 days. In terms of relative price strength the Atara Biotherapeutics share price has underperformed the S&P500 Index by -18.43% over the past year.
What are the analyst and broker recommendations for Atara Biotherapeutics?
The overall consensus recommendation for Atara Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Atara Biotherapeutics dividend yield?
Atara Biotherapeutics does not currently pay a dividend.
Does Atara Biotherapeutics pay a dividend?
Atara Biotherapeutics does not currently pay a dividend.
When does Atara Biotherapeutics next pay dividends?
Atara Biotherapeutics does not currently pay a dividend.
How do I buy Atara Biotherapeutics shares?
To buy shares in Atara Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atara Biotherapeutics?
As of the previous close price of $9.23, shares in Atara Biotherapeutics had a market capitalisation of $61.78m.
Where are Atara Biotherapeutics shares listed?
Here are the trading details for Atara Biotherapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ATRA
What kind of share is Atara Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Atara Biotherapeutics is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atara Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Atara Biotherapeutics is $15.33. That is 66.09% above the last closing price of $9.23.
Analysts covering Atara Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.56 for the next financial year.
Find out moreWhat is the trend in the Atara Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atara Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -44.66%.
As of the last closing price of $9.23, shares in Atara Biotherapeutics were trading +4.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atara Biotherapeutics PE Ratio?
The Atara Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atara Biotherapeutics?
Atara Biotherapeutics' management team is headed by:
- Ronald Renaud - CHM
- Pascal Touchon - PRE
- Utpal Koppikar - CFO
- Joseph Newell - COO
- Jakob Dupont - EVP
- K. Amar Murugan - SVP
- Kristin Yarema - SVP
- Carol Gallagher - LED
- Ameet Mallik - DRC
- Maria Roncarolo - DRC
- Roy Baynes - IND
- Eric Dobmeier - IND
- Matthew Fust - IND
- William Heiden - IND
- Beth Seidenberg - IND